The MHRA has authorised GSK’s Nucala (mepolizumab) in the UK as an add‑on maintenance treatment for adults with uncontrolled ...

STORM Therapeutics has entered a new collaboration with US‑based AlidaBio to accelerate the development of cancer therapies that target RNA modifications.

Bial has introduced a new sublingual formulation of apomorphine in the UK, offering a fresh treatment option for adults with Parkinson’s disease who experience intermittent OFF episodes that are not ...

HUTCHMED has advanced its ongoing study of surufatinib and camrelizumab for treatment‑naïve metastatic pancreatic ductal ...

Zenas BioPharma has announced positive findings from its phase 3 INDIGO trial evaluating obexelimab in patients with ...

Acesion Pharma has begun enrolling patients into a phase 2 clinical trial of AP31969, its novel oral SK ion channel inhibitor being developed for rhythm control in atrial fibrillation.

Johnson & Johnson has submitted a Type II variation application to the European Medicines Agency for an extension of ...

The inaugural Excellence in Healthcare Partnerships (EHP) Awards and Networking Evening is taking place at the Grand Connaught Rooms, London at 5pm on 5th February 2026. An evening of discussion, ...

The move significantly expands and diversifies AbbVie’s revenue base AbbVie has wrapped up its $63 billion acquisition of Allergan plc following receipt of regulatory approval from all government ...

Early-stage study reveals strong immune response and safety profile for ACI-35.030 AC Immune SA has announced peer-reviewed results from its phase 1b/2a trial of two Tau-targeting active ...

JHU083 reduced tumour growth and triggered tumour cell death in mice Researchers from the Johns Hopkins Kimmel Cancer Center and Johns Hopkins Drug Discovery have revealed that a novel therapy can ...

SMC approves targeted therapy for patients with EGFR exon 20 insertion mutations Johnson & Johnson has welcomed the decision by the Scottish Medicines Consortium (SMC) to accept Rybrevant (amivantamab ...